Fu, Kai <br/><br/>
SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.  [electronic resource] 

 -  Arteriosclerosis, thrombosis, and vascular biology  Apr 2008 
 - 665-71 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4636 
<br/><br/><label>Standard No.: </label>10.1161/ATVBAHA.107.158030  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Activin Receptors, Type I--antagonists & inhibitors<br/>Adenosine Triphosphate--metabolism<br/>Administration, Oral<br/>Animals<br/>Azabicyclo Compounds--administration & dosage<br/>Binding Sites<br/>Carotid Artery Injuries--drug therapy<br/>Cell Line<br/>Fibroblasts--drug effects<br/>Fibrosis<br/>Humans<br/>Male<br/>Myoblasts, Smooth Muscle--drug effects<br/>Protein Kinase Inhibitors--administration & dosage<br/>Protein Serine-Threonine Kinases--antagonists & inhibitors<br/>Rats<br/>Rats, Sprague-Dawley<br/>Receptor, Transforming Growth Factor-beta Type I<br/>Receptors, Transforming Growth Factor beta--antagonists & inhibitors<br/>Transforming Growth Factor beta--physiology